Breaking News

PAREXEL In Korean Drug Development Alliance

Aims to accelerate global drug development and commercialization

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

PAREXEL was selected by the Korea Drug Development Fund (KDDF) to help Korean companies develop and commercialize healthcare products for the global market. With assets of $1 billion, the KDDF is a consortium of three health-related Korean ministries established in September 2011 to develop at least 10 new drugs by 2019 for the global market. The alliance with PAREXEL aims to enhance its development network and gain access to a broad range of drug development support services for its selected in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters